Clostridium difficile — More Difficult Than Ever CP Kelly, JT LaMont New England Journal of Medicine 359 (18), 1932-1940, 2008 | 1873 | 2008 |
Clostridium difficile colitis CP Kelly, C Pothoulakis, JT LaMont New England Journal of Medicine 330 (4), 257-262, 1994 | 1649 | 1994 |
Clostridium difficile Infection DA Leffler, JT Lamont New England Journal of Medicine 372 (16), 1539-1548, 2015 | 1565 | 2015 |
Choline, an essential nutrient for humans SH Zeisel, KA Da Costa, PD Franklin, EA Alexander, JT Lamont, ... Faseb Journal 5 (7), 2093-2098, 1991 | 722 | 1991 |
Clostridium difficile Infection CP Kelly, JT LaMont Annual review of medicine 49 (1), 375-390, 1998 | 637 | 1998 |
Saccharomyces boulardii Protease Inhibits the Effects of Clostridium difficile Toxins A and B in Human Colonic Mucosa I Castagliuolo, MF Riegler, L Valenick, JT LaMont, C Pothoulakis Infection and immunity 67 (1), 302-307, 1999 | 629 | 1999 |
Mucin biophysics R Bansil, E Stanley, JT LaMont Annual review of physiology 57 (1), 635-657, 1995 | 522 | 1995 |
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. G Hecht, C Pothoulakis, JT LaMont, JL Madara The Journal of clinical investigation 82 (5), 1516-1524, 1988 | 483 | 1988 |
Role of Gallbladder Mucus Hypersecretion in the Evolution of Cholesterol Gallstones: STUDIES IN THE PRAIRIE DOG SP Lee, JT Lamont, MC Carey The Journal of clinical investigation 67 (6), 1712-1723, 1981 | 479 | 1981 |
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. M Riegler, R Sedivy, C Pothoulakis, G Hamilton, J Zacherl, G Bischof, ... The Journal of clinical investigation 95 (5), 2004-2011, 1995 | 460 | 1995 |
Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum C Pothoulakis, CP Kelly, MA Joshi, N Gao, CJ O'Keane, I Castagliuolo, ... Gastroenterology 104 (4), 1108-1115, 1993 | 409 | 1993 |
Clostridium difficile infection: a worldwide disease KE Burke, JT Lamont Gut and liver 8 (1), 1, 2014 | 388 | 2014 |
Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum I Castagliuolo, JT Lamont, ST Nikulasson, C Pothoulakis Infection and immunity 64 (12), 5225-5232, 1996 | 379 | 1996 |
Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life S Jangi, JT Lamont Journal of pediatric gastroenterology and nutrition 51 (1), 2-7, 2010 | 374 | 2010 |
Saccharomyces boulardii Stimulates Intestinal Immunoglobulin A Immune Response to Clostridium difficileToxin A in Mice A Qamar, S Aboudola, M Warny, P Michetti, C Pothoulakis, JT LaMont, ... Infection and immunity 69 (4), 2762-2765, 2001 | 357 | 2001 |
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin DYM Leung, CP Kelly, M Boguniewicz, C Pothoulakis, JT LaMont, ... The Journal of pediatrics 118 (4), 633-637, 1991 | 346 | 1991 |
Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells I Castagliuolo, JT Lamont, B Qiu, SM Fleming, KR Bhaskar, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 271 (5 …, 1996 | 342 | 1996 |
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis J Salcedo, S Keates, C Pothoulakis, M Warny, I Castagliuolo, JT LaMont, ... Gut 41 (3), 366-370, 1997 | 328 | 1997 |
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. C Pothoulakis, I Castagliuolo, JT Lamont, A Jaffer, JC O'Keane, ... Proceedings of the National Academy of Sciences 91 (3), 947-951, 1994 | 312 | 1994 |
Aspirin prevention of cholesterol gallstone formation in prairie dogs SP Lee, MC Carey, JT LaMont Science 211 (4489), 1429-1431, 1981 | 283 | 1981 |